Split Decision In Breach-of-Contract Battle Of Litigation War Between ChromaDex, Elysium
Consolidated Advertising Complaints Continue, ChromaDex Appeals Patent-Infringement Loss
Executive Summary
California federal court jury found both breached contracts: Elysium failed to pay for nicotinamide riboside and pterostilbene it ordered and received, while ChromaDex violated pricing provision in supply agreement.
You may also be interested in...
ChromaDex Ordered To Pay Elysium’s Attorney Fees
“So lacking in substance that it ‘stands out’ from the dozens of [patent infringement] challenges I have encountered as a judge in the last five years,” says Colm Connolly, Delaware district chief judge. His ruling doesn’t end the firms’ litigation as related cases continue in federal courts in California and New York.
In NAC Docket, NAD+ Drug Firm Suggests US FDA Get Serious About Dietary Ingredient Regulations
MetroBiotech argues it and other drug developers and manufacturers are harmed as FDA allows NAD+ use in dietary supplements without requiring new dietary ingredient notifications and despite DSHEA’s preclusion clause.
Attention Shoppers And Investors: ChromaDex Makes Tru Niagen Available At Walmart
Tru Niagen products available at 3,800 US Walmart stores include a lower dose, 100 mg, that ChromaDex didn't previously market. Launch sparks heavy trading driving up firm's share price.